Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a single center, "modified standard design" dose escalation study designed to
determine the maximum tolerated, minimum efficacious dose (MTD/MED) of IL-15 (Intravenous
Recombinant Human IL-15) and incidence of donor natural killer (NK) cell expansion by day +14
when given after haploidentical donor NK cells in patients with relapse or refractory acute
myelogenous leukemia (AML).